Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...

Regeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of another BCMAxCD3 bispecific drug in the multiple myeloma (MM) treatment space.

The maximum tolerated dose (MTD) was defined as ixabepilone 40 mg/m 2 plus capecitabine 2000 mg/m 2 daily for schedule A. Tumor Response (Phase II).

Wegovy is a prescription injection used for weight loss and reduction of cardiovascular risks. Learn about its dose escalation, form, strengths, and more.

Capecitabine and advanced gastric cancer -- what is on the horizon? Learn more from two recent randomized Phase III trials that show promise for the future.

Learn about the dosages for Botox in treating migraine, incontinence, muscle spasticity, and more. You can also find information on how the drug’s given.